2026 Global: Animal Source Feed Enzymes Market -Competitive Review (2032) report
Description
The 2026 Global: Animal Source Feed Enzymes Market -Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for animal source feed enzymes market by geography and historical trend. The scope of the report extends to sizing of the animal source feed enzymes market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Zoetis Inc., Boehringer Ingelheim, Merck & Co., Inc., Elanco Animal Health, and Ceva Santé Animale lead the Animal Parasiticides Market as the top five major companies. Zoetis dominates with its extensive portfolio of parasiticides like Simparica Trio, a monthly chewable tablet protecting dogs from heartworm, ticks, fleas, roundworms, and hookworms, backed by US FDA approval and strong R&D investments. The company reported US$8.5 billion in 2023 animal health revenues, driven by companion animal parasiticides, dermatology, and pain treatments, solidifying its global leadership through innovation in vaccines, pharmaceuticals, and diagnostics. Boehringer Ingelheim follows with USD 4.7 billion in sales, offering broad-spectrum parasiticides alongside vaccines for livestock and pets, emphasizing respiratory, infectious, and reproductive health solutions. Merck & Co., Inc. (Animal Health) excels in pharmaceuticals and next-generation vaccines, promoting One Health initiatives, antimicrobial stewardship, and sustainability amid regulatory shifts. Elanco, post its $7.6 billion acquisition of Bayer's animal health unit in 2020, integrates legacy parasiticides brands, enhancing its position in a consolidated market.
Virbac, Vetoquinol, Bayer AG, Perrigo Company PLC, and Sanofi complete the top ten, focusing on specialized parasiticides and strategic expansions. Virbac pioneers vaccines, parasiticides, and nutritional supplements with regional customization and sustainability, addressing preventive care for companion and commercial animals. Vetoquinol, under Soparfin SCA, specializes in anti-parasite solutions, anti-infectives, and generics for cats, dogs, cattle, and pigs, achieving US$571 million in 2023 revenues through competitive pricing in price-sensitive markets. Bayer AG contributes legacy brands in parasiticides, with ongoing R&D alongside Sanofi and Zoetis for new technologies, despite divestitures boosting competitors like Elanco. Perrigo Company PLC targets over-the-counter parasiticides, leveraging generics for broad accessibility in the growing market projected from $5.1 billion in 2018 to $7.1 billion by 2026. Sanofi supports the segment via animal health investments, joint ventures, mergers, and product developments to counter parasites affecting animal welfare.
These companies drive market concentration through innovation, acquisitions, and global reach amid rising zoonotic threats and resistance challenges. Leaders like Zoetis, Merck, Boehringer, Elanco, and Ceva hold significant shares, with others like Virbac and Vetoquinol enhancing competitiveness via telemedicine, digital platforms, and tailored solutions for livestock productivity and pet care. Strategic moves, including Elanco's Bayer deal and Zoetis's product launches, reflect adaptation to consumer demands, regulatory pressures, and tariff impacts, fostering growth in both mature and emerging regions. Overall, the top ten—Zoetis, Boehringer Ingelheim, Merck, Elanco, Ceva, Virbac, Vetoquinol, Bayer, Perrigo, and Sanofi—navigate a dynamic landscape, prioritizing R&D in novel parasiticides to inhibit parasite growth and ensure animal health.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for animal source feed enzymes market by geography and historical trend. The scope of the report extends to sizing of the animal source feed enzymes market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Zoetis Inc., Boehringer Ingelheim, Merck & Co., Inc., Elanco Animal Health, and Ceva Santé Animale lead the Animal Parasiticides Market as the top five major companies. Zoetis dominates with its extensive portfolio of parasiticides like Simparica Trio, a monthly chewable tablet protecting dogs from heartworm, ticks, fleas, roundworms, and hookworms, backed by US FDA approval and strong R&D investments. The company reported US$8.5 billion in 2023 animal health revenues, driven by companion animal parasiticides, dermatology, and pain treatments, solidifying its global leadership through innovation in vaccines, pharmaceuticals, and diagnostics. Boehringer Ingelheim follows with USD 4.7 billion in sales, offering broad-spectrum parasiticides alongside vaccines for livestock and pets, emphasizing respiratory, infectious, and reproductive health solutions. Merck & Co., Inc. (Animal Health) excels in pharmaceuticals and next-generation vaccines, promoting One Health initiatives, antimicrobial stewardship, and sustainability amid regulatory shifts. Elanco, post its $7.6 billion acquisition of Bayer's animal health unit in 2020, integrates legacy parasiticides brands, enhancing its position in a consolidated market.
Virbac, Vetoquinol, Bayer AG, Perrigo Company PLC, and Sanofi complete the top ten, focusing on specialized parasiticides and strategic expansions. Virbac pioneers vaccines, parasiticides, and nutritional supplements with regional customization and sustainability, addressing preventive care for companion and commercial animals. Vetoquinol, under Soparfin SCA, specializes in anti-parasite solutions, anti-infectives, and generics for cats, dogs, cattle, and pigs, achieving US$571 million in 2023 revenues through competitive pricing in price-sensitive markets. Bayer AG contributes legacy brands in parasiticides, with ongoing R&D alongside Sanofi and Zoetis for new technologies, despite divestitures boosting competitors like Elanco. Perrigo Company PLC targets over-the-counter parasiticides, leveraging generics for broad accessibility in the growing market projected from $5.1 billion in 2018 to $7.1 billion by 2026. Sanofi supports the segment via animal health investments, joint ventures, mergers, and product developments to counter parasites affecting animal welfare.
These companies drive market concentration through innovation, acquisitions, and global reach amid rising zoonotic threats and resistance challenges. Leaders like Zoetis, Merck, Boehringer, Elanco, and Ceva hold significant shares, with others like Virbac and Vetoquinol enhancing competitiveness via telemedicine, digital platforms, and tailored solutions for livestock productivity and pet care. Strategic moves, including Elanco's Bayer deal and Zoetis's product launches, reflect adaptation to consumer demands, regulatory pressures, and tariff impacts, fostering growth in both mature and emerging regions. Overall, the top ten—Zoetis, Boehringer Ingelheim, Merck, Elanco, Ceva, Virbac, Vetoquinol, Bayer, Perrigo, and Sanofi—navigate a dynamic landscape, prioritizing R&D in novel parasiticides to inhibit parasite growth and ensure animal health.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.